Table 2.

Intergroup comparison of key efficacy endpoints at 1 yr

	ATG (n = 113)	Daclizumab (n = 114)	P value
BPAR	17 (15.0%)	31 (27.2%)	0.016
Borderline changes	2	3
Grade I	8	5
Grade IIa	3	13
Grade IIb	1	5
Grade III	2	4
Pure AMR	1	1
Steroid-resistant rejection	3 (2.7%)	17 (14.9%)	0.002
Median time to rejection (d) [interquartile range 25 to 75%]	35 [13 to 164]	13 [9 to 19]	0.007
Recurrent rejection	4 (3.6%)	7 (6.1%)	0.54
Delayed graft function	35 (31.5%)	50 (44.6%)	0.044
Graft loss	20 (17.7%)	16 (14.0%)	0.47
From death with functioning graft	3 (2.7%)	4 (3.5%)
From primary nonfunction	3 (2.7%)	2 (1.8%)
From vascular thrombosis	2 (1.8%)	1 (0.9%)
From uncontrolled rejection	3 (2.7%)	3 (2.6%)
From hemolytic uremic syndrome	2 (1.8%)	1 (0.9%)
From technical failure	2 (1.8%)	1 (0.9%)
From BK virus	2 (1.8%)	0
From other causes	3 (2.7%)	4 (3.5%)
Death	5 (4.4%)	4 (3.5%)	0.75
From stroke	2 (1.8%)	0
From sepsis	2 (1.8%)	1 (0.9%)
From bleeding	0	1 (0.9%)
From cancer	1 (0.9%)	0
From cardiac arrest	0	1 (0.9%)
Unknown cause	0	1 (0.9%)